about
Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular DystrophyAttempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle.Defects in mitochondrial ATP synthesis in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency.BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice.Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.Chemotherapeutic agents induce mitochondrial superoxide production and toxicity but do not alter respiration in skeletal muscle in vitro.Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15.Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology.
P50
Q26772002-62334686-8F54-443B-BE83-11108460137FQ33586004-91E4CDD2-F6FD-486D-B356-CFFB6249BE6FQ34776381-D4FBDB19-DABF-4137-A614-CF54A2B178AFQ37742823-F90C7EF6-96F3-4F70-98B1-3F2CBCAFB8A1Q38831900-F0672EF0-605A-4C5E-B5A6-8D4D1F8A48C7Q39330717-6C87EB79-E815-4A3D-B074-C8DBF10F747DQ46273027-3002A9DE-623C-45A0-94C7-9AD7280090E2Q47773940-FCECE0E5-9F65-40EA-A4F7-E42F839E9E27Q47966217-2504D7B3-7C03-47B3-B882-189AE13B6E98
P50
description
investigador
@es
researcher
@en
name
Cara A Timpani
@en
type
label
Cara A Timpani
@en
prefLabel
Cara A Timpani
@en
P31
P496
0000-0003-4567-4319